Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Intervention not reported

Intervention (no. of studies/participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

The review found no eligible studies for this question.

1 finding from 1 review

Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Intervention (no. of studies/participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…

The review found no eligible studies for this question.

1 finding from 1 review

Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Intervention (no. of studies/participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

The review found no eligible studies for this question.

1 finding from 1 review

Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found